SAFETY AND EFFICACY OF ONCE-WEEKLY CARFILZOMIB DOSING IN FRAIL PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE 3 A.R.R.O.W. STUDY
Author(s): ,
Maria-Victoria Mateos
Affiliations:
University Hospital Salamanca/IBSA,Salamanca,Spain
,
Heinz Ludwig
Affiliations:
Wilhelminen Cancer Research Institute,Wilhelminenspital,Austria
,
Shaji Kumar
Affiliations:
Mayo Clinic,Rochester,United States
,
Cara Rosenbaum
Affiliations:
Weill Cornell Medicine,New York,United States
,
Mei Huang
Affiliations:
Amgen Inc,Thousand Oaks,United States
,
Amanda Goldrick
Affiliations:
Amgen Inc,Thousand Oaks,United States
,
Julie Blaedel
Affiliations:
Amgen Inc,Thousand Oaks,United States
Meletios Dimopoulos
Affiliations:
University Athens School of Medicine,Athens,Greece
EHA Library. Mateos M. Jun 15, 2019; 266996; PS1379
Dr. María-Victoria Mateos
Dr. María-Victoria Mateos
Contributions
Abstract

Abstract: PS1379

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
A.R.R.O.W. demonstrated superior progression-free survival (PFS) with once-weekly carfilzomib (K, 70 mg/m2) and dexamethasone (Kd70) vs twice-weekly K (27 mg/m2) and dexamethasone (Kd27) in relapsed and refractory (RRMM) patients (pts), regardless of age. For a comprehensive measure of fitness, frailty scales were developed incorporating age, comorbidities, and functional status (Palumbo Blood 2015;125:2068–74; Facon Blood 2015;126:4239).

Aims
Here, we assessed post-hoc pt outcomes by frailty status.

Methods
PFS and safety were assessed by treatment arm and a frailty algorithm which incorporated age, Charlson Comorbidity Index derived from medical history, and ECOG performance status; pts with frailty scores of 0, 1, or ≥2 were classified as fit, intermediate, or frail, respectively. PFS was assessed using the Kaplan-Meier method. Safety was assessed in pts who received ≥1 treatment dose.

Results
The distribution of pts by frailty status was generally balanced between treatment arms (Table). Once-weekly Kd70 vs twice-weekly Kd27 resulted in median PFS for fit, intermediate, and frail pts of 15.7 vs 5.7 months (hazard ratio [HR] 0.53 [95% confidence interval (CI), 0.33–0.86]), 11.1 vs 7.7 months (HR 0.81 [95% CI, 0.55–1.19]), and 10.3 vs 6.6 months (HR 0.76 [95% CI, 0.49–1.16]), respectively.

 

Rates of grade ≥3 treatment-emergent adverse events (TEAEs) of interest were similar between treatment arms across frailty subgroups (Table). In the once-weekly Kd70 subgroups, there was no grade ≥3 peripheral neuropathy and grade ≥3 cardiac failure rates were ≤4%.

 

 

Conclusion
Once-weekly Kd70 resulted in PFS benefits vs twice-weekly Kd27, regardless of frailty level. These results support weekly Kd70 as a treatment option for fit and frail RRMM pts.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Multiple myeloma, Proteasome inhibitor


© 2019 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2019 ASCO Annual Meeting. All rights reserved.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies